|
歐元 / 歐羅
|
參與該交易的銀行周一上午表示, 首次公開募股 的 認購 已被投資者多次超額 認 ... IPO 將為CVC提供資金,以在房地產等領域進行更多收購,並可能為去年宣布... |
|
同花順(300033)美股訊 4月18日Citigroup維持ProQR Therapeutics評級為中性,最新目標價為2.00美元。 ProQR Therapeutics於3月13日發布2023年年報,公司截至2023年12月31日,營業收入952.50萬歐元,同比118.51%,淨利潤-2773.50萬歐元,基本每股收益 |
|
香港文匯報訊 華為近日宣布進軍歐洲市場,推出全新「nova 12」系列智能手機,涵蓋3款主要機型,售價介乎280至500歐元(約2,337至4,174港元),是華為智能手機中較為經濟實惠的機型。歐洲傳媒分析,nova 12手機無法直接登上Google Play應用程式 |
≫More |
|
Name |
Updated |
Value |
Change |
Change % |
FTSE |
04-22 19:45 |
8026.7 |
▲ 130.81 |
▲ 1.66% |
CHF/HKD |
04-25 06:58 |
8.5685 |
▲ 0.004 |
▲ 0.04% |
EUR/HKD |
04-25 07:00 |
8.3701 |
▲ 0.02 |
▲ 0.3% |
GBP/HKD |
04-25 06:59 |
9.734 |
▲ 0.06 |
▲ 0.59% |
CAC 40 |
04-22 19:45 |
8040.8 |
▲ 18.4 |
▲ 0.23% |
DAX |
04-22 19:32 |
17811.1 |
▲ 73.69 |
▲ 0.42% |
≫More |
|
|
|
Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.
|
|